HIGHLIGHTS
- What: As a result, the purpose of this study was to investigate the cost-effectiveness of tislelizumab plus Frontiers in Pharmacology
- Who: Ramon Andrade Bezerra De and colleagues from the Universidade Nove Julho, Brazil have published the research work: Cost-effectiveness analysis of tislelizumab plus chemotherapy as the fi rst-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China, in the Journal: (JOURNAL) of 18/05/2023
- How: The authors conducted deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) to test the robustness of the economic evaluation model.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.